

Analyses of Patient-Reported Outcomes (PROs) With Mirvetuximab Soravtansine (MIRV) Versus Standard Chemotherapy in the Randomized Phase 3 FORWARD I Study in Ovarian Cancer (GOG 3011)

Jiuzhou Wang,¹³ Michael J. Birrer,¹⁴ Ignace Vergote¹⁵ ¹⁵Katholieke Universiteit Leuven, Leuven, Belgium

BACKGROUND

- Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate (ADC) comprising a folate receptor alpha (FR α)-binding antibody, cleavable linker, and maytansinoid DM4 payload, a potent tubulin-targeting agent¹
- MIRV has demonstrated clinically meaningful antitumor activity with a favorable safety profile in patients with FR α -positive^a ovarian cancer as monotherapy and in combination^{2,3}
- During the phase 3 FORWARD I trial, patient-reported outcomes (PROs) regarding chemotherapy side effects, cancer-specific symptoms, and quality of life (QoL) were collected⁴
- Preplanned and exploratory analyses of PRO data were conducted to determine differences with MIRV vs chemotherapy and to inform the collection of PRO data in subsequent trials with MIRV (eg, phase 3 MIRASOL; NCT04209855)

^aAntitumor activity with MIRV has been demonstrated with single-agent MIRV in FR α -high PROC (\geq 75% tumor cells FR α -positive by PS2+)² and in combination with other agents in FR α low-to-high PROC (\geq 25% tumor cells FR α -positive by PS2+).³

Methods

- The phase 3, open-label, randomized trial FORWARD I (N=366; NCT02631876) enrolled patients with platinum-resistant FR α -positive advanced epithelial ovarian cancer (EOC)^a
- Patients were randomized 2:1 to receive MIRV (n=248; 6 mg/kg AIBW^b once every 3 weeks) or investigator's choice of chemotherapy (IC chemo^c, n=118)
- Patients completed PRO assessments (Table 1) during screening, on day 1 of cycle 1, every 9 weeks thereafter (±1 week) until disease progression, and at the end of treatment visit
- Differences between treatment groups (LPP analysis population^d) were assessed by descriptive statistics, Chi-squared analysis, Fisher's exact test, stratified Kaplan-Meier curves, unadjusted log-rank *P* values, and odds ratios

males is calculated as 0.9*height (cm) - 92. cInvestigator's choice of chemotherapy was specified by investigators before randomization: paclitaxel, 80 mg/m² on days 1, 8, and 15 every 4 weeks; PLD, 40 mg/m² once every 4 weeks; topotecan, 4 mg/m² on days 1, 8, and 15 every 4 weeks or 1.25 mg/m² on days 1 to 5 every 3 weeks. ^dThe LPP analysis included all patients within each of the parent populations (ITT and FRa high) who (1) survived, (2) remained in the study from screening through to the day of a given assessment, and (3) had available QoL data for baseline and day of assessmen

Table 1. FORWARD I PRO Assessments				
PRO assessment	Description			
EORTC QLQ-C30 (C30)	A 30-item questionnaire designed to assess the QoL in patients with cancer by measuring functional domains, symptoms, and global QoL/health status			
EORTC QLQ-OV28 (OV28)	A 28-item ovarian cancer supplemental module developed to augment the C30 with 3 multi-item functional scales and 5 multi-item symptom scales			
FOSI	An 8-item measure of symptom response to treatment for ovarian cancer			

PRO Analyses


Primary: Minimally important difference (MID) response in abdominal/GI symptoms at week 8/9 by OV28 Abdominal/GI symptom subscale score:

- ≥15-point increase: Improved
- <15-point increase: Not improved

Secondary: Time to symptom worsening

Kathleen N. Moore,¹ Amit M. Oza,² Nicoletta Colombo,³ Ana Oaknin,⁴ Giovanni Scambia,⁵ Domenica Lorusso,⁶ Susana Banerjee,⁷ Conleth G. Murphy,⁸ Jason A. Konner,⁹ Peter C. Lim,¹⁰ Monica Prasad-Hayes,¹¹ Bradley J. Monk,¹²

¹College of Medicine, The University of Oklahoma, Oklahoma City, OK, USA; ²University Health Network, Princess Margaret Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; ⁵Agostino Gemelli IRCCS, Rome, Italy; ⁷Royal Marsden Hospital, London, UK; ⁸Bon Secours Cork and Cancer Trials Ireland; ⁹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ¹⁰Center Of Hope, Reno, NV, USA; ¹¹Icahn School of Medicine at Mount Sinai, New York, NY, USA; ¹²University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Arkansas Medical School, Little Rock, AR, USA; ¹⁴Winthrop P. Rockefeller Cancer Institute, University of Ark




tumor cells with any FR α membrane staining visible at \leq 10× microscope objective; one patient randomized to the IC chemo arm was subsequently determined to have a FR α expression level <50%.

Results: OV28 Abdominal/GI Scale

The proportion of patients with a \geq 15-point improvement on the OV28 Abdominal/GI scale at week 8/9 was significantly higher in the MIRV ITT group vs IC chemo (Figure 1)

Patients with high FR α expression who were treated with MIRV demonstrated similar improvements; however, these findings did not reach statistical significance compared with IC chemo (Figure 1)



 Compared with the respective IC chemo populations, the likelihood of abdominal/GI symptoms on the OV28 was (Figure 3): 70% lower in the MIRV ITT population (95% CI, 0.15-0.60; P=0.0007) 80% lower in the MIRV FRα-high population (95% CI, 0.10-0.54; P=0. Similar results for the likelihood of symptom deterioration with MIRV v all other OV28 subscales, including chemotherapy side effects, sexuali severity (peripheral neuropathy), and body image (Figure 3) General improvements were also observed with MIRV on the ovarian car FOSI assessment (Figure 3) Figure 3. Odds Ratios for Categorical Change on the OV28 and FOSI: MIRV vs IC Longitudinal Period Population 	0007) ere observed on y, hair loss, pain
 all other OV28 subscales, including chemotherapy side effects, sexualis severity (peripheral neuropathy), and body image (Figure 3) General improvements were also observed with MIRV on the ovarian car FOSI assessment (Figure 3) Figure 3. Odds Ratios for Categorical Change on the OV28 and FOSI: MIRV vs IC Longitudinal Period Population FRα High OV28 Abdominal/GI Hormonal Body image 	ty, hair loss, pain ncer-specific
FOSI assessment (Figure 3) Figure 3. Odds Ratios for Categorical Change on the OV28 and FOSI: MIRV vs IC Longitudinal Period Population FRα High OV28 Abdominal/GI Peripheral neuropathy Hormonal Body image	
Longitudinal Period Population FRα High OV28 Abdominal/GI Peripheral neuropathy Hormonal Body image	Chemo in the
FRα High● OV28 ← Favors MIRV Favors IC chemo Abdominal/GI ↓	
Peripheral neuropathy Hormonal Body image	P value ^a
Hormonal Hormonal	P=0.0007 P=0.0007
Body image	<i>P</i> =0.0042 <i>P</i> =0.0092
	<i>P</i> =0.0011 <i>P</i> =0.0039
Attitude toward disease	<i>P</i> =0.0291 <i>P</i> =0.0174
	<i>P</i> =0.0227 <i>P</i> =0.0069
hemotherapy side effects	<i>P</i> =0.0001 <i>P</i> =0.001
Hair loss	<i>P</i> <0.0001 <i>P</i> <0.0001
Sexuality	P=0.0027 P=0.0004
FOSI	P=0.0002 P=0.0009
· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·

CONCLUSIONS

- Analysis of PROs from FORWARD I found that MIRV demonstrated a statistically significant benefit over IC chemo for the number of patients achieving a 15-point improvement on the OV28 Abdominal/GI symptom subscale at week 8/9
- Improved PROs were observed with MIRV treatment compared with IC chemo across multiple symptoms, including chemotherapy side effects, sexuality, hair loss, pain severity, body image, and general improvement in ovarian cancer-specific symptoms on the FOSI
- Symptom benefits occurring with MIRV, such as time to symptom worsening, were observed exclusively or more profoundly in the FR α -high population
- The results from these analyses will inform the design of future PRO analyses with MIRV

These positive PRO findings, in conjunction with the safety profile of MIRV in recurrent ovarian cancer along with significant antitumor activity support MIRV as a potential new standard of care for patients with FR α -positive ovarian cancer

AIBW, adjusted ideal body weight; C30, EORTC Quality of Life Questionnaire-core 30; DM4, N2'-[4-[(3-carboxypropyl)dithio]-4-methyl-1-oxo-2-sulfopentyl]-N2'-deacetylmaytansine; ECOG PS, Eastern Cooperative Oncology Group Performance Status; EOC, epithelial ovarian cancer; EORTC, European Organisation for Research and Treatment of Cancer; FOSI, Functional Assessment of Cancer; F IC chemo, investigator's choice of chemotherapy; ITT, intention to treat; LPP, Longitudinal Period Population; LS, least squares; MID, minimally important difference; MIRV, mirvetuximab soravtansine; mTSW, median time to symptom worsening; OV28, EORTC Quality of Life Questionnaire-Ovarian Cancer Module; PARPi, poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitor; PLD, pegylated liposomal doxorubicin; PRO, patient-reported outcome; PS2+, positive staining intensity ≥2; QoL, quality of life; TSW, time to symptom worsening. References: 1. Moore KN, et al. Cancer. 2017;123(16):3080-3087. 2. Matulonis UA, et al. Presented at: 2022 American Society of Clinical Oncology Congress; 1. Moore KN, et al. Presented at: 2018 European Society for Medical Oncology Congress; October 19-23, 2018; Munich, Germany. Abstract 949P. 4. Moore KN, et al. Ann Oncol. 2021;32(6):757-765.

Dr Moore reports the following financial relationships: Consulting/Advising with Aravive, Alkermes, AstraZeneca, Blueprint Pharma, Clovis, Eisai, Elevar, GSK/Tesaro, Genentech/Roche, Hengrui, ImmunoGen, InxMed, Imab, Lilly, Mereo, Merck, Myriad, Mersana, OncXerna, OncoNova, OncoNova, OncoNova, Consulting/Advising with Aravive, Alkermes, AstraZeneca, Blueprint Pharma, Clovis, Eisai, Elevar, GSK/Tesaro, Genentech/Roche, Hengrui, ImmunoGen, InxMed, Imab, Lilly, Mereo, Merck, Myriad, Mersana, OncXerna, OncoNova, OncoNova, Consulting/Advising with Aravive, Alkermes, AstraZeneca, Blueprint Pharma, Clovis, Eisai, Elevar, GSK/Tesaro, Genentech/Roche, Hengrui, ImmunoGen, InxMed, Imab, Lilly, Mereo, Merck, Myriad, Mersana, OncXerna, OncoNova, Consulting/Advising with Aravive, Alkermes, AstraZeneca, Blueprint Pharma, Clovis, Eisai, Elevar, GSK/Tesaro, Genentech/Roche, Hengrui, ImmunoGen, InxMed, Imab, Lilly, Mereo, Merck, Myriad, Mersana, OncXerna, OncoNova, Novartis, Tarveda, VBL Therapeutics, and Verastem; Research funding from PTC Therapeutics, Lilly, GSK/Tesaro, and Merck; Associate directorship with GOG Partners; Sits on director's board for The GOG Foundation, Inc. Acknowledgements: The study described here was sponsored by ImmunoGen, Inc. The authors would like to especially thank the patients who consented to be included in the FORWARD I trial as well as their families. Editorial assistance in the preparation of this poster was provided by PRECISIONscientia, funded by ImmunoGen, Inc. Studies described here were sponsored by ImmunoGen, Inc. Copies of this poster (including those obtained through Quick Response [QR] Code) are for personal use only and may not be reproduced without permission from ESMO or the author of this poster.

Results: Changes in C30 Physical Functioning Scores

Analyses of C30 demonstrated a statistically significant benefit in physical functioning for MIRV over IC chemo in both the ITT and FR α -high populations

Table 3. Model-Based Change from Baseline on C30 Physical Functioning Scale by Treatment Group Over All Cycles^a

	ITT population		FR α -high population	
C30 physical functioning (revised)	MIRV (n=248)	IC chemo (n=118)	MIRV (n=147)	IC chemo (n=71)
LS mean overall change (SE)	-0.21 (2.59)	-4.31 (2.89)	-0.79 (4.71)	-6.81 (5.11)
LS mean difference from IC chemo (SE)	4.10 (1.96)		6.03 (2.33)	
95% CI	0.25-7.96		1.42-10.63	
<i>P</i> value ^b	0.0369		0.0106	

The primary model includes treatment, time (continuous), treatment*time, baseline PRO score, age, race, and 3 stratification variables (prior lines of therapy, FRa levels, and chemo).^bP value for LS mean treatment difference =

Results: Categorical Changes and TSW on the FOSI

- Categorical change analyses of FOSI scores demonstrated that by cycle 7:
- 88.9% of ITT population patients on IC chemo had declined vs 70.3% with MIRV
- 88.1% of FR α -high population patients on IC chemo had declined vs 65.0% with MIRV

